Home  /  Resource Library  /  Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma

Results of a phase II study investigating dose adjusted chemotherapy plus rituximab in first line treatment of DLBCL.